

# Jon M Wigginton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10764562/publications.pdf>

Version: 2024-02-01

30  
papers

26,754  
citations

318942

23  
h-index

591227

27  
g-index

30  
all docs

30  
docs citations

30  
times ranked

31613  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination immunotherapy: a road map. , 2017, 5, 16.		325
2	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .		11
3	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
4	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. Journal of Clinical Oncology, 2015, 33, 2013-2020.	0.8	385
5	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB / Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
6	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. Journal of Clinical Oncology, 2014, 32, 1020-1030.	0.8	2,015
7	Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2013, 369, 122-133.	13.9	3,776
8	Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).. Journal of Clinical Oncology, 2013, 31, CRA9006-CRA9006.	0.8	41
9	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Medicine, 2012, 366, 2443-2454.	13.9	10,727
10	High-Throughput Molecular and Histopathologic Profiling of Tumor Tissue in a Novel Transplantable Model of Murine Neuroblastoma: New Tools for Pediatric Drug Discovery. Cancer Investigation, 2012, 30, 343-363.	0.6	9
11	Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 2012, 366, 2455-2465.	13.9	6,820
12	Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 2011, 9, 214.	1.8	139
13	Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology, 2011, 132, 226-239.	2.0	111
14	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clinical Cancer Research, 2011, 17, 3064-3076.	3.2	108
15	Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow. Journal of Immunology, 2009, 182, 4328-4338.	0.4	90
16	Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opinion on Biological Therapy, 2007, 7, 1705-1721.	1.4	191
17	Multicolor Fluorescence-Based Approaches for Imaging Cytokine-Induced Alterations in the Neovascularization, Growth, Metastasis, and Apoptosis of Murine Neuroblastoma Tumors. Journal of Immunotherapy, 2006, 29, 151-164.	1.2	8
18	Therapeutic Modulation of Akt Activity and Antitumor Efficacy of Interleukin-12 Against Orthotopic Murine Neuroblastoma. Journal of the National Cancer Institute, 2006, 98, 190-202.	3.0	13

#	ARTICLE	IF	CITATIONS
19	Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors. <i>Journal of Immunology</i> , 2006, 176, 6302-6312.	0.4	32
20	IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells. <i>Journal of Immunology</i> , 2004, 173, 7170-7182.	0.4	151
21	Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses. <i>Journal of Immunology</i> , 2003, 170, 2727-2733.	0.4	105
22	Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN- $\gamma$ and Fas-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-2. <i>Journal of Immunology</i> , 2002, 169, 4467-4474.	0.4	66
23	IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 513-524.	1.4	43
24	Primary Hepatocytes from Mice Treated with IL-2/IL-12 Produce T Cell Chemoattractant Activity that Is Dependent on Monokine Induced by IFN- $\gamma$ (Mig) and Chemokine Responsive to $\gamma$ -2 (Crg-2). <i>Journal of Immunology</i> , 2001, 166, 3763-3770.	0.4	33
25	Complete Regression of Established Spontaneous Mammary Carcinoma and the Therapeutic Prevention of Genetically Programmed Neoplastic Transition by IL-12/Pulse IL-2: Induction of Local T Cell Infiltration, Fas/Fas Ligand Gene Expression, and Mammary Epithelial Apoptosis. <i>Journal of Immunology</i> , 2001, 166, 1156-1168.	0.4	48
26	IFN- $\gamma$ and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. <i>Journal of Clinical Investigation</i> , 2001, 108, 51-62.	3.9	110
27	IFN- $\gamma$ -Dependent Delay of In Vivo Tumor Progression by Fas Overexpression on Murine Renal Cancer Cells. <i>Journal of Immunology</i> , 2000, 164, 231-239.	0.4	69
28	Interleukin-12: Murine Models of a Potent Antitumor Agent. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 266-274.	1.8	26
29	Evaluation of the Antitumor Activity of the Interleukin-12/Pulse Interleukin-2 Combination. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 434-439.	1.8	9
30	Antitumor activity of interleukin 12 in preclinical models. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, S16-S21.	1.1	77